BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T155514Z
CREATED:20260813T155514Z
LAST-MODIFIED:20260813T155514Z
UID:44179-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:World CNS Summit South Korea
DESCRIPTION:The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted\, mechanism-differentiated therapies for neurodegenerative\, rare neurodevelopmental\, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation\, the summit convenes biopharma leaders\, translational scientists\, and drug developers to explore the next generation of CNS therapeutics and accelerate progress from discovery through early clinical development. \nThe agenda highlights advances in disease-modifying approaches\, blood-brain barrier delivery technologies\, RNA-based therapeutics\, gene therapies\, neuroinflammation\, biomarkers\, and novel targets beyond traditional amyloid and tau pathways. Attendees will gain insights from leading organizations including ABL Bio\, AriBio\, Johnson & Johnson\, Eli Lilly\, Novartis\, Takeda\, AbbVie\, Lundbeck\, Angelini Pharma and many more. \nDesigned to foster meaningful scientific exchange and strategic collaboration\, the summit provides a valuable platform to connect with Korean biotech innovators\, global pharmaceutical companies\, and external innovation leaders evaluating the next wave of CNS opportunities. For decision-makers shaping neuroscience pipelines\, partnerships\, and licensing strategies\, it offers a focused view of the technologies\, modalities\, and therapeutic approaches driving the future of CNS drug development. \nFind out more today: https://ter.li/jrf94t4n
URL:https://www.pharmajournalist.com/event/world-cns-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T160546Z
CREATED:20260813T160546Z
LAST-MODIFIED:20260813T160546Z
UID:44189-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:10th Complement-Based Drug Development Summit
DESCRIPTION:The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies\, developers are focused on identifying the right targets\, modalities\, and indications to drive differentiation and patient impact. Recent milestones\, including Regeneron’s cemdisiran advancing through FDA and EMA review and Biogen’s acquisition of Apellis\, highlight the growing momentum and investment shaping the next era of complement therapeutics. \nAs the industry’s only dedicated forum uniting complement leaders\, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics\, including: \n\nAdvancing clinical success through biomarker innovation\, improved target engagement strategies\, robust trial design\, and smarter indication selection to de-risk development\n\n\nBenchmarking next-generation modalities across siRNA\, gene therapy\, biologics\, and novel delivery technologies to improve durability\, efficacy\, safety\, and patient outcomes\n\n\nExpanding beyond C3 and C5 to evaluate intracellular complement biology\, emerging targets\, novel mechanisms\, and combination approaches shaping the next generation of complement therapeutics\n\n\nUnlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative\, ocular\, autoimmune\, haematological\, oncology\, and acute indications\n\nWhat to Expect: \n\n80+ Experts Dedicated to Complement\n\n\n18+ Data-Driven Presentations\n\n\n7+ Hours of Meaningful Networking\n\n\n2 Discussion-Led Workshops\n\n\n1 Scientific Poster Session\n\nBringing together biotech innovators\, pharma leaders\, and academic KOLs\, this industry-led anniversary meeting provides a focused opportunity to advance novel targets\, refine modality strategy\, navigate clinical development\, and expand into new indications. \nBy attending\, you’ll be in the room with: Annexon Biosciences\, Apellis Pharmaceuticals\, Cascade Biotechnology\, Complement Therapeutics\, Graviton Biosciences\, Genentech\, Grid Therapeutics\, Ikarovec\, Inflarx\, Regeneron\, Ripple Therapeutics\, Sanofi and more! \nAcross 3 days of discussion-led workshops\, data-driven presentations\, clinical insights\, and expert panels\, engage with the leaders behind renal readouts\, next-generation targets\, and emerging CNS and ophthalmology programs to benchmark your approach\, strengthen differentiation\, and build partnerships that de-risk complement drug development. \nDiscover the 10th Anniversary Meeting program here: https://ter.li/2yscb7oh
URL:https://www.pharmajournalist.com/event/10th-complement-based-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261211
DTSTAMP:20261001T143517Z
CREATED:20261001T143450Z
LAST-MODIFIED:20261001T143517Z
UID:44456-1796774400-1796947199@www.pharmajournalist.com
SUMMARY:3rd Obesity & Weight Loss Drug Development Summit West
DESCRIPTION:Optimizing Tolerability\, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development \nAs obesity drug development enters a defining new chapter\, the race is no longer about developing the next GLP-1\, but delivering the next breakthrough in tolerability\, muscle preservation\, patient adherence\, precision medicine\, and long-term outcomes. With hundreds of obesity assets in development and billions of dollars invested in the space\, 2026 is a pivotal moment for companies to differentiate their pipelines\, benchmark their strategies\, and secure their position in the market. \nThe 3rd Obesity & Weight Loss Drug Development Summit West is where the industry’s most innovative pharma and biotech leaders come together to answer the questions that will shape the next decade of obesity therapeutics. While many events focus on clinical readouts or broad discussions around obesity care\, this summit is dedicated to the practical challenges and strategic decisions driving drug development success. \nBringing together 80+ senior executives\, and decision-makers\, this intimate\, industry-focused forum offers unparalleled opportunities to exchange insights\, build meaningful partnerships\, and understand what today’s innovation really means for tomorrow’s therapies. If you’re serious about advancing next-generation obesity therapeutics\, this is the room you need to be in. \nTo know more visit: https://ter.li/hexuee5e
URL:https://www.pharmajournalist.com/event/3rd-obesity-weight-loss-drug-development-summit-west/
LOCATION:Sheraton Mission Valley San Diego Hotel\, 1433 Camino Del Rio South\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR